Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: Significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy

Internal Medicine

Volumn 49, Issue 15, 2010, Pages 1469-1476

  Miyamoto, Masaki ^a   Manabe, Noriaki ^b   Haruma, Ken ^b  

^a Hiroshima Prefecture Hiroshima Hospital   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

FSSG questionnaire; GERD (gastro esophageal reflux disease); GERD questionnaire; PPI; Prokinetics

Indexed keywords

LANSOPRAZOLE; MOSAPRIDE CITRATE; OMEPRAZOLE; RABEPRAZOLE;

ADULT; AGE; ARTICLE; BLOATING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DYSPEPSIA; FEMALE; FREQUENCY SCALE FOR THE SYMPTOMS OF GERD; GASTROINTESTINAL MOTILITY DISORDER; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; NON EROSIVE REFLUX DISEASE; PROSPECTIVE STUDY; REFLUX ESOPHAGITIS; SCORING SYSTEM;

ADULT; AGE FACTORS; CONSTIPATION; DRUG RESISTANCE; DRUG SYNERGISM; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HEARTBURN; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956216749     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3615     Document Type: Article

References (29)

1. Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol 39: 888-891, 2004.
2. Kusano M, Shimoyama Y, Kawamura O, et al. Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients. Dig Dis Sci 52: 1673-1677, 2007.
3. Armstrong D, Dent J, Bennett JR, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 111: 85-92, 1996.
4. Hoshihara Y. Reflux esophagitis. In: Atlas of Gastroenterologic Endoscopy by High-Resolution Video-Endoscope. Nagasako K, Fujimori T, Hoshihara Y, Tabuchi M, Eds. Igaku-Shoin, Tokyo, 1998: 32.
5. Yoshida N, Kato S, Ito T. Mosapride Citrate. Drug of the Future 18: 513-515, 1993.
6. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal disease. Scand J Gastroenterol 28(Suppl 199): 18-21, 1993.
7. Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastrooesophageal reflux disease in general practice. BMJ 322: 344-347, 2001.
8. Crawley JA, Schmitt CM. How satisfied are chronic heartburn suffers with their prescription medications? Results of the Patient Unmet Needs Study. J Clin Outcomes Manag 7: 29-34, 2000.
9. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: protonpump inhibitor failure in gastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther 22: 79-94, 2005 (Review).
10. Fass R. Proton pump inhibitor failure-What are the therapeutic options?. Am J Gastroenterol 104(Suppl 2): S33-S38, 2005 (Review).
11. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitor. Gut 58: 295-309, 2009 (Review).
12. Carlsson R, Dent J, Bolling-Stenevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastronterol 33: 1023-1029, 1998.
13. Svedlund J, Sjodin I, Dotevall G. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcers. Dig Dis Sci 33: 129-134, 1998.
14. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36). Med Care 30: 473-481, 1992.
15. Stanghellini V, Armstrong D, Monnikes H, Bardhan KD. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther 19: 463-479, 2004.
16. Lee SK, Lee KJ, Kim SJ, Cho SW. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion 79: 196-201, 2009.
17. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 130: 1466-1479, 2006 (Review).
18. Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 14: 1593-1603, 2000.
19. Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Strategy for treatment of ninerosive reflux disease in Asia. World J Gastroenterol 14: 3123-3128, 2008 (Review).
20. Bredenoord AJ, Smout AJ. Refractory gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 20: 217-223, 2008.
21. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333: 1106-1110, 1995.
22. Madan K, Ahuja V, Kashyap PC, Sharma MP. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus 17: 274-278, 2004.
23. http://www.fda.gov/bbs/topics/ANSWERS/ANS01007.htm/
24. Ruth M, Finizia C, Cange L, Lundell L. The effect of mosapride on oesophageal motor function in patients with gastro-oesophageal reflux. Eur J Gastroenterol Hepatol 15: 1115-1121, 2003.
25. Ruth M, Hamelin B, Rohss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 12: 35-40, 1998.
26. Miyamoto M, Haruma K, Takeuchi K, Kuwabara M. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol 23: 746-751, 2008.
27. Arai K, Takeuchi Y, Watanabe H, Tsukurimichi A, Uchida N, Imawari M. Prokinetics influence the pharmacokinetics of rabeprazole. Digestion 78: 67-71, 2008.
28. Hiyama T, Matsuo K, Urabe Y, et al. Meta-analysis used to identify factors associated with the effectiveness of proton pump inhibitors against non-erosive reflux disease. J Gastroenterol Hepatol 24: 1326-1332, 2009.
29. Lin M, Gerson LB, Lascar R, Davila M, Triadafilopoulos G. Features of gastroesophageal reflux disease in women. Am J Gastroenterol 99: 1442-1447, 2004.